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Palladin promotes invasion of pancreatic cancer cells by
enhancing invadopodia formation in cancer-associated fibroblasts
SM Goicoechea1,8, R Garcı́a-Mata1,8, J Staub1, A Valdivia1,8, L Sharek1, CG McCulloch2, RF Hwang3, R Urrutia4, JJ Yeh5,6,7,
HJ Kim6,7,9 and CA Otey1,6,9
The stromal compartment surrounding epithelial-derived pancreatic tumors is thought to have a key role in the aggressive
phenotype of this malignancy. Emerging evidence suggests that cancer-associated fibroblasts (CAFs), the most abundant cells in
the stroma of pancreatic tumors, contribute to the tumor’s invasion, metastasis and resistance to therapy, but the precise molecular
mechanisms that regulate CAFs behavior are poorly understood. In this study, we utilized immortalized human pancreatic CAFs to
investigate molecular pathways that control the matrix-remodeling and invasion-promoting activity of CAFs. We showed previously
that palladin, an actin-associated protein, is expressed at high levels in CAFs of pancreatic tumors and other solid tumors, and also
in an immortalized line of human CAFs. In this study, we found that short-term exposure of CAFs to phorbol esters reduced the
number of stress fibers and triggered the appearance of individual invadopodia and invadopodial rosettes in CAFs. Molecular
analysis of invadopodia revealed that their composition resembled that of similar structures (that is, invadopodia and podosomes)
described in other cell types. Pharmacological inhibition and small interfering RNA knockdown experiments demonstrated that
protein kinase C, the small GTPase Cdc42 and palladin were necessary for the efficient assembly of invadopodia by CAFs. In
addition, GTPase activity assays showed that palladin contributes to the activation of Cdc42. In mouse xenograft experiments using
a mixture of CAFs and tumor cells, palladin expression in CAFs promoted the rapid growth and metastasis of human pancreatic
tumor cells. Overall, these results indicate that high levels of palladin expression in CAFs enhance their ability to remodel the
extracellular matrix by regulating the activity of Cdc42, which in turn promotes the assembly of matrix-degrading invadopodia in
CAFs and tumor cell invasion. Together, these results identify a novel molecular signaling pathway that may provide new molecular
targets for the inhibition of pancreatic cancer metastasis.
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INTRODUCTION
Pancreatic cancer (pancreatic ductal adenocarcinoma) is one of
the most aggressive malignancies found in humans. Although
pancreatic cancer is relatively rare, it is the fourth leading cause of
cancer-related deaths in the United States because of its high
lethality (95–98% mortality rate within 5 years) and pattern of
early metastasis.1 It is now well established that both the extra-
cellular matrix (ECM) and the cells within the stromal compart-
ment surrounding epithelial-derived cancer cells contribute to the
progression of pancreatic cancer and many other types of solid
tumors.2–4 The most abundant cells in the tumor stroma are
cancer-associated fibroblasts (CAFs), also known as carcinoma-
associated fibroblasts (CAFs) or tumor myofibroblasts. Emerging
evidence suggests that CAFs contribute to tumor progression
through the secretion of pro-invasive and pro-proliferative growth
factors, and through the generation of growth-enhancing
mechanical signals.5–7 This hypothesis has been confirmed in
mice, using mixed-cell recombination approaches in which
neoplastic cells are injected either with or without
accompanying CAFs. With a variety of cancer cell types, mixing
the neoplastic cells with CAFs results in the formation of larger
tumors and more metastases when compared with injecting
neoplastic cells alone.8–10 Thus, CAFs are likely to be critical players
in the process of tumor progression and invasion, which highlights
the importance of understanding the molecular mechanisms that
control the invasion-promoting activities of CAFs. A recent study
using an innovative cell culture system demonstrated an active
role for CAFs in tumor invasion via remodeling of the ECM.11 This
study showed that CAFs can generate channels within the matrix
that create passage ways for the metastasizing tumor cells. These
data suggest that matrix remodeling by CAFs actively promotes
the collective invasion of tumor epithelial cells.
Palladin is an actin-associated protein that is expressed at high
levels in the CAFs of pancreatic tumors and other invasive tumor
types.12–14 Palladin has an essential role in the assembly and
maintenance of multiple types of actin-dependent structures,
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including stress fibers, dynamic dorsal ruffles and matrix-
degrading podosomes in vascular smooth muscle cells.15,16
Palladin was first shown to have a role in protrusive motility in
knockdown experiments with cultured cells, in which palladin
expression was found to be required for neurite extension in
cortical neurons.17 More recently, the phenotype of the palladin
null mouse (embryonic lethal, with defects in body wall closure
both dorsally and ventrally) demonstrate that palladin has an
essential role in normal cell motility during embryonic
development.18 Our recently published results have established
that a specific variant of palladin (isoform 4) is dramatically
upregulated in CAFs at an early stage in the development of
pancreatic tumors.13 In addition, we showed previously that
palladin upregulation is specific to highly invasive ductal
adenocarcinomas and was not observed in less invasive types of
pancreas tumors.13 A correlation between high palladin levels in
the stroma and poor clinical prognosis was also demonstrated in
renal cancer, suggesting a specific role for palladin in the
metastasis-promoting behavior of CAFs.14 Here, we show that,
on stimulation with phorbol esters, CAFs are able to form
invadopodia, a matrix-degrading actin-rich structure that is
normally found in invasive cell types. The formation of
invadopodia in CAFs is modulated by the small GTPase Cdc42
and by palladin expression levels. In addition, we show that
palladin has a role in the regulation of Cdc42 activity. Finally, we
show that palladin expression enhances the invasive behavior of
CAFs in vitro and also tumor progression in vivo. Together, these
results suggest that CAFs utilize palladin-dependent signaling
pathways to remodel the ECM, which in turn promotes metastasis
of tumor cells.
RESULTS
Invadopodia formation and matrix degradation in pancreatic CAFs
Accumulating evidence suggests that the ability of tumor cells to
cross a basement membrane is facilitated by specialized
subcellular structures termed invadopodia.19,20 Both invadopodia
and structurally similar organelles termed podosomes are actin-
based membrane protrusions that are enriched with matrix
metalloproteinases. These structures have been described in
several types of tumor cells and hematopoietic cells,21,22 but
invadopodia formation in human CAFs has not been described
previously. This gap in knowledge has been partially due to the
absence of reliable CAF cell line models of the type used in the
current study. We examined the ability of CAFs, which were
isolated from collagenase-treated human pancreatic tumors, to
form invadopodia in response to short-term treatment with
phorbol esters. This treatment is widely used to stimulate the
assembly of invadopodia and podosomes in other cell types.23
CAFs were treated with phorbol 12-myristate 13-acetate (PMA),
fixed and labeled with rhodamine–phalloidin to visualize F-actin
(Figure 1a). Untreated CAFs showed typical actin stress fibers
spanning the cell body. After 1 h of treatment, most cells showed
increased membrane ruffling activity, and the number of stress
fibers was strongly reduced. In addition, actin puncta became
visible either behind the leading edge or clustered within the cell
body, with about 30% of cells displaying both individual puncta
and rosettes (Figure 1b).
We analyzed the presence of known invadopodia markers to
determine whether the actin-rich puncta formed in CAFs in
response to phorbol esters were invadopodia. Adhesion-associated
and actin-binding proteins (such as vinculin and cortactin) were
found in the invadopodia-like structures of CAFs (Supplementary
Figure S1). As protein kinase C (PKC) mediates phorbol ester-
stimulated podosome and invadopodia formation in several cell
lines,23–25 we determined whether PKC also regulates assembly of
invadopodia in CAFs. Cells were pre-treated with the PKC inhibitor
Gö6976 for 30min, and then activated by PMA (60min in the
presence of the inhibitor). The PKC inhibitor reduced the number
and percentage of cells that formed invadopodia by threefold
(Figure 1c; Po0.05), indicating that PKC has a role in PMA-induced
invadopodia formation in CAFs.
A defining trait of the invadopodia described in tumor cells is
their ability to degrade the ECM.20,26,27 To determine if the
invadopodia detected in CAFs possess this property, we performed
a well-established in vitro matrix degradation assay.28 CAFs were
seeded onto glass coverslips pre-coated with fluorescently labeled
gelatin and treated for 1 h with PMA. The black dots in the
fluorescent gelatin represent areas of focal degradation of the
matrix (Figure 1d). These dots colocalized with actin-rich invado-
podia in CAFs, indicating that in these cells, PKC stimulation results
in the assembly of actin-rich, matrix-degrading structures that
closely resemble the invadopodia described in invasive epithelial
cancer cells. Taken together, these data show that PKC-dependent,
matrix-degrading invadopodia are not unique to neoplastic and
hematopoietic cells but can also form in CAFs.
CAFs are known to express a-smooth muscle actin, and thus are
considered to be a type of myofibroblast, and phenotypically
distinct from normal fibroblasts. To ask if normal fibroblasts share
with CAFs the ability to assemble invadopodia, we treated normal
primary human fibroblasts with phorbol esters, then fixed and
stained the cells with phalloidin. Neither individual invadopodia nor
invadopodial rosettes were detected in normal fibroblasts
(Figure 2a). To extend our observations to activated myofibroblasts
from other sources, we utilized immortalized cell lines (immortalized
mouse pancreatic stellate cells clone 2 (imPSC-C2) and imPSC-C3)
from activated stellate cells isolated from mouse pancreas.29,30
Previous studies have established that activated stellate cells are a
major source myofibroblasts in the fibrotic pancreas, and of CAFs in
pancreas tumors. We tested the ability of these mouse pancreatic
myofibroblasts to form invadopodia in response to phorbol ester
stimulation. Both imPSC-C2 and imPSC-C3 were treated with two
phorbol esters, PMA and phorbol-12,13-dibutyrate (PDBu), fixed and
labeled with rhodamine–phalloidin to visualize F-actin. Invadopodia
were found both individually and in rosettes in both clones of
imPSC shortly after addition of either PMA (Figure 2b) or PBDu
(Supplementary Figure S2). As a final confirmation that CAFs can
assemble invadopodia, we assayed the ability of primary CAFs to
respond to phorbol ester treatment, using both mouse CAFs
obtained from a xenografted human tumor, and human CAFs
cultured from an explanted patient sample. Invadopodia were
detected in both types of primary CAFs (Supplementary Figure S3).
We showed previously that primary and immortalized human CAFs
have high levels of palladin when compared with normal
fibroblasts.13 To investigate palladin levels in imPSC-C2 and
imPSC-C3, we performed western blot analysis using human
normal gingival fibroblasts as a control. As expected, the two
mouse PSC clones show that palladin is upregulated when
compared with normal fibroblasts (Figure 2c), and similar to the
levels detected in human CAFs. The expression levels of palladin
were normalized against those of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and the results are presented in Figure 2d.
Approximately a fivefold increase in palladin levels were detected in
the activated myofibroblasts compared with normal fibroblasts.
These results suggest that a high level of palladin expression is a
relevant molecular feature underlying the mechanism that governs
invadopodia formation in activated myofibroblasts.
Palladin localizes to PMA-induced invadopodia and enhances
invadopodia formation after phorbol ester stimulation
To determine whether palladin is recruited to invadopodia of
CAFs, immunostaining was used to visualize endogenous palladin
after stimulation with PMA. Palladin was strongly enriched in the
invadopodia and colocalized with actin in cells that were double-
stained with anti-palladin antibodies and phalloidin (Figure 3a).
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To determine the functional role of palladin in the assembly of
invadopodia, we examined the effect of inactivating this gene on
the cellular response of CAFs to PMA. Small interfering RNA
(siRNA) oligos were used to knockdown the expression of palladin.
Western blot analysis showed a B90% reduction of palladin
expression in CAFs (siRNA) compared with cells treated with
control siRNA (CTRL; Figure 3b). The ability of CAFs to form
invadopodia was strongly impaired when palladin expression was
silenced (Figure 3c). Palladin knockdown reduced the percentage
of cells that form invadopodia by more than twofold (Po0.05;
Figure 3c). These results reveal that palladin has an important role
in invadopodia formation in CAFs.
Cdc42 is involved in PMA-induced invadopodia assembly
Cdc42 is considered a master regulator of the core actin poly-
merization machinery found in invadopodia in vascular smooth
muscle cells, metastatic rat carcinoma mammary cells and human
melanoma cells.31–33 Although Cdc42 has been reported to have a
role in podosome and invadopodia formation in multiple cell lines,
the cellular function of Cdc42 in CAFs is largely unexplored.
To determine the role of Cdc42 in invadopodia formation in CAFs,
we examined the effect of Cdc42 knockdown on the cellular
response to PMA. Western blot analysis showed that treatment
with Cdc42 siRNA reduced Cdc42 expression by 90% in CAFs
(siRNA) compared with cells treated with control siRNA (CTRL;
Figure 4a). When Cdc42-knockdown cells were treated with PMA,
a large percentage of the siRNA-transfected cells were unable to
form invadopodia. Indeed, Cdc42 knockdown reduced the
percentage of cells that form invadopodia by fourfold
(Figure 4b; Po0.05), demonstrating that Cdc42 has an important
role in regulating the assembly of invadopodia in CAFs.
Palladin regulates the activity of Cdc42
We have previously shown that palladin has a role in the
regulation of Rac1 activity in vascular smooth muscle cells.16 Rac1
and Cdc42 pathways can share the same components, and in
many cases they bind to the same effectors and can be activated
by the same guanine nucleotide exchange factors (GEFs).34 This
led us to speculate that palladin may also be modulating Cdc42
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Figure 1. PMA treatment induces invadopodia formation and matrix degradation in human CAFs. Human CAFs were treated for 1 h with PMA,
fixed and stained with rhodamine–phalloidin to visualize F-actin. Boxes indicate individual invadopodia and rosettes. (a) Representative
pictures of individual invadopodia and rosettes. (b) Time course of invadopodia formation. (c) Effect of 0.1mM PKC inhibitor Gö6976 on
invadopodia formation. Invadopodia formation was significantly decreased after treatment of CAFs with PKC inhibitor (PKC inh, 10%) as
compared with control cells (untreated, 32%). (d) CAFs were cultured on Alexa-488-labeled gelatin-coated coverslips overnight, and then
treated with PMA for 1 h before fixation. Cells were then fixed and stained with rhodamine–phalloidin to visualize actin-rich invadopodia.
Arrowheads denote invadopodia-degrading matrix and the degradation sites. Scale bar¼ 10mm.
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GTP-bound state and an inactive GDP-bound state, and the active
form can be isolated using an affinity precipitation approach.35,36
We used this standard pull-down assay to investigate the activity
of Cdc42 in CAFs. Overall levels of Cdc42 expression do not differ
between control and palladin KD cells, but the pool of active
Cdc42 is significantly reduced when palladin expression is either
transiently knocked down using siRNA or stably knocked down
using lentiviral delivery of short hairpin RNA (shRNA1, shRNA2), as
shown in Figure 5a. Cdc42 activity in the palladin knockdown cells
decreased on average 460% (Figure 5b; Po0.05), demonstrating
that the activity of this GTPase is decreased in the absence of
palladin expression.
Palladin enhances in vitro invasion of pancreatic cancer cells
CAFs have been shown previously to promote the invasion of
tumor cells by creating channels in the ECM.11 Our finding that
palladin may be required for invadopodia formation motivated us
to determine whether palladin expression is critical for the
invasion-promoting activity of CAFs. We used a mixed-cell
in vitro invasion assay that uses Matrigel-coated invasion
chambers. Human pancreatic tumor cells (AsPC-1) were
fluorescently labeled with CellTracker red and placed in the
upper chamber together with control CAFs (AsPC-1þ CTRL CAFs)
or with palladin knockdown CAFs (AsPC-1þ shRNA1 CAFs).
AsPC-1 cells with no CAFs were used as a control (AsPC-1
alone). The cells were allowed to invade for 24 h and then the non-
invading cells were removed from the upper well. The invading
cells were fixed and the red AsPC-1 cells were counted.
These results show that there is a twofold (Po0.05) increase in
the number of AsPC-1 cells that invade through the Matrigel-
coated membranes in the presence of control CAFs compared
with AsPC-1 cells alone (Figure 6). In contrast, in the presence of
palladin knockdown CAFs, no significant increase (P¼ 0.29)
in the number of invading AsPC-1 cells was observed. Importantly,
the effect on palladin depletion in CAFs on AsPC-1 migration was
rescued by re-expressing an shRNA-resistant palladin construct
(Figure 6).
The cancer stroma is usually composed of fibrillary collagen,
predominantly type I. To assess the invasion-promoting activity of
CAFs on this type of matrix, we performed a mixed-cell in vitro
invasion assay using collagen I-coated invasion chambers. Results
show that there is a twofold (Po0.05) increase in the number of
AsPC-1 cells that invade through the collagen-coated membranes
in the presence of control CAFs compared with AsPC-1 cells alone
(Figure 7). In contrast, no significant increase in the number of
invading AsPC-1 cells was observed in the presence of palladin
knockdown CAFs (shRNA1, P¼ 0.58; shRNA2, P¼ 0.62). These
results indicate that palladin-expressing stromal cells promote
in vitro invasion of pancreatic tumor epithelial cells through either
Matrigel or collagen.
Palladin enhances in vivo invasion of pancreatic cancer cells
Along with others, we have shown previously that the high levels
of palladin observed in samples of bulk pancreas tumors are due
to palladin overexpression in stromal fibroblasts and not in
neoplastic cells.12,13,37 We also showed that palladin levels in the
stroma correlate closely with tumor invasiveness in pancreas
tumors, suggesting that palladin overexpression may have a
critical role in CAF behavior.13 Thus, to evaluate if palladin
expression in CAFs promotes tumor growth in vivo, we used a
mixed-cell xenograft study. The stable knockdown CAFs were
mixed with AsPC-1 cells before implantation into the pancreata of
immunodeficient mice, following a well-established protocol.38,39
In parallel, mice were injected with AsPC-1 cells mixed with
control CAFs, or AsPC-1 cells alone (no CAFs). The proportion of
CAFs in the co-injection relative to tumor cells was 1:3 tumor-to-
CAF ratio, which reflects the relative abundance of stromal cells
typically observed in human pancreatic adenocarcinomas.
To accurately monitor in vivo tumor growth, AsPC-1 cells were
stably transfected with luciferase, and bioluminescence imaging



















































Figure 2. Mouse PSCs form invadopodia after phorbol ester treatment and contain high levels of palladin. (a) Human normal fibroblasts (hNFs)
were treated with phorbol esters (50 ng/ml PMA and 1 mM phorbol-12,13-dibutyrate (PDBu)), fixed and stained with rhodamine–phalloidin to
visualize F-actin. (b) Immortalized mouse PSC clone C2 (imPSC-C2) and immortalized mouse PSC clone 3 (imPSC-C3) were treated with PMA,
fixed and stained with rhodamine–phalloidin to visualize F-actin. Boxes indicate individual invadopodia and rosettes. Scale bar¼ 10 mm.
(c) Whole-cell lysates of human CAFs, mPSC-C2 and mPSC-C3 were analyzed by western blot using the palladin monoclonal antibody 1E6.
Blots were also stained for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a control for equal loading. (d) Quantification of palladin
protein levels in hPSC, imPSC-C3, imPSC-C2 and human normal gingival fibroblasts (hNF). The ratio of palladin to total cellular GAPDH is
shown on the left axis.
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of the mice was performed weekly as previously described.40
Similar to the pattern that is typical of pancreas cancer in human
patients, the AsPC-1 cells formed primary tumors at the site of
injection and also metastasized locally within the abdomen
(Figure 8a). To measure the whole-body tumor load for each
animal, total photon flux was used (Figure 8b). Our results show
that in animals where neoplastic cells were mixed with control
CAFs, tumor growth was dramatically enhanced as compared with
mice injected with tumor cells alone, in agreement with published
results,10 validating the expected behavior of this system. In
contrast, palladin knockdown CAFs were significantly less efficient
in promoting tumor progression than control, palladin-expressing
CAFs (Figure 8b; Po0.05). The possibility of CAF-induced
tumorigenesis in the absence of carcinoma cells was ruled out
previously by the absence of tumor development in a control
group of animals inoculated with CAFs only.10 These results, using
well-controlled in vivo models, are congruent with our in vitro
experiments, and demonstrate that palladin expression critically
contributes to the acquisition of the pro-proliferative, pro-invasive
phenotype of pancreatic CAFs. Thus, we conclude that palladin is a
novel regulator of pancreatic cancer growth and invasion, at least
in part via its important effects on the behavior of CAFs. Together,
these results extend our understanding on how palladin regulates
pancreatic cancer pathobiology through the modulation of the
tumor microenvironment.
DISCUSSION
A growing body of literature supports the idea that tumor–stromal
interactions have a key role in the initiation and progression of
solid tumors, especially in cancers with a robust desmoplastic
component such as pancreatic ductal adenocarcinoma. We have
shown previously that the actin-associated protein palladin
(isoform 4) is dramatically upregulated in both primary and
immortalized CAFs cultured from human pancreatic ductal
adenocarcinoma explants.13 Here, we examined the role of
palladin in the invasion-promoting activity of pancreatic CAFs in
culture and in a mouse model of tumor progression. We used two
different in vitro systems to assess the impact of palladin in matrix
remodeling. First, we monitored invadopodia formation on the
matrix protein gelatin; second, we assayed cell invasion through
two different substrates: Matrigel (which is a complex mixture of
matrix molecules including laminin, collagen type IV and entactin)
and collagen (85% type I and 15% type III, which are main
components of the desmoplastic tumor stroma). Our results show
that pancreatic CAFs are able to form functional, matrix-degrading
invadopodia, and also demonstrate that palladin expression in
CAFs promotes invasion through tumor stroma. In addition, we
show that the small GTPase Cdc42 has a critical role in the
formation of CAFs’ invadopodia, and that palladin levels correlate
with Cdc42 activity, suggesting that palladin contributes to the
regulation of Cdc42 during invadopodia formation. In mouse
xenograft experiments using a mixture of CAFs and tumor cells,
palladin expression in CAFs promoted the rapid growth and
metastasis of human pancreatic tumor cells that were co-injected
with CAFs. These data indicate that in intact animals, palladin is
directly involved in facilitating tumor cell migration through the
ECM, which is enriched with collagens type I and III. Taken
together, these results indicate that CAFs utilize palladin-
dependent pathways to activate Cdc42, assemble invadopodia
and remodel important and abundant matrix molecules, which in
turn may promote the ability of tumor cells to invade across a
basement membrane.
The mode of invasion that is induced by invadopodia requires
fast assembly of cell-matrix adhesions, efficient proteolysis of the
matrix and a dynamic actin cytoskeleton. Tissue invasion is most
efficient when these cellular processes are coordinated. Many
actin–cytoskeleton-associated proteins act as major players in the
Src-mediated organization of adhesive interactions such as
podosomes and invadopodia. Moreover, there is growing




























Figure 3. Palladin localizes to invadopodia and enhances invado-
podia formation. (a) CAFs were treated for 1 h with PMA. After
fixation, endogenous palladin was detected by immunofluores-
cence. Co-labeling with tetramethyl rhodamine isothiocyanate
(TRITC)-phalloidin and polyclonal anti-palladin antibody reveals that
palladin colocalizes with actin. Scale bar¼ 10mm. (b) CAFs trans-
fected with control siRNA oligos (CTRL) and siRNA oligos targeting
palladin (siRNA) were treated with PMA for 1 h. Invadopodia
formation was significantly reduced in palladin knockdown cells
(siRNA, 16% of total cells displaying invadopodia), as compared with
control cells (CTRL, 36% of total cells displaying invadopodia).
Results are representative of three independent experiments in
which at least 300 transfected cells were counted. Po0.05, Student’s
t-test. (c) Western blot analysis was used to detect palladin levels in
























Figure 4. Cdc42 regulates invadopodia assembly in CAFs. Human
CAFs transfected with control siRNA oligos and siRNA oligos
targeting Cdc42 were treated with PMA for 1 h. (a) Western blot
analysis was used to detect Cdc42 levels in cells treated with control
oligos (C) or Cdc42-specific siRNA oligos (KD). (b) Invadopodia
formation was significantly reduced (Po0.05) in Cdc42 knockdown
cells (KD, 9%), as compared with control cells (C, 35%). Results are
representative of three independent experiments in which at least
300 transfected cells were counted.
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tumorigenic and metastatic processes of various human tumors.
Indeed, the balance between actin regulators might determine
the type of adhesive structure that is formed and could
account for the differences in shape and dynamics of invado-
podia and podosomes.41 Thus, it is not surprising that the
actin-binding protein palladin has an important role in the
assembly of invadopodia. In addition to its role as an actin-
binding and -bundling protein, palladin functions as a cytoskeletal
scaffolding molecule, as it interacts with a large number of actin-
binding proteins with important roles in organizing actin filament
arrays. Palladin’s proline-rich domain binds directly to the actin-
regulating proteins VASP (and its relatives Mena and EVL), pro-
filin (actin polymerization), Eps8 (actin capping and bundling),
SPIN90 (actin polymerization) and ArgBP2.16,42–45 In addition,
palladin binds to a-actinin, a widely expressed actin-crosslinking
protein, and to Src itself, a kinase that is known to promote the
assembly of invadopodia and podosomes. Studies from Luo
et al.18 have shown that fibroblasts from a palladin knockout
mouse display defects in cell motility, cell adhesion and actin
organization, demonstrating that normal palladin levels are
required for normal actin assembly. In addition, we have
previously shown that palladin influences the activity of Rac1,
which is a member of Rho family of GTPases.16 As Rho family
members are key regulators of actin organization, the current
evidence suggests that palladin influences actin organization
through at least three distinct mechanisms: via direct crosslinking
of F-actin, binding to multiple actin-regulatory proteins
and altering the activity of Rho family members. All three
of these molecular activities may contribute to the assembly of
invadopodia in CAFs.
A growing body of evidence connects the Rho family of
GTPases (RhoA, Rac1 and Cdc42) to cancer cell migration, invasion
and metastasis.46,47 The deleterious role of Rho GTPases in human
cancer stems from their overexpression or hyperactivation rather
than the presence of activating point mutations.48 This suggests
that their regulatory proteins, guanine-nucleotide exchange
factors (GEFs) and GTPase-activating proteins (GAPs), have a
critical role in dysregulated signaling during human cancer
































Figure 5. Palladin regulates the activity of Cdc42. (a) Western blot
analysis of whole-cell lysates from palladin transient knockdown
CAFs using control siRNA (CTRL) or siRNA targeting palladin (siRNA;
left panel), and palladin stable knockdown CAFs using lentivirus
(shRNA1 and shRNA2; right panel). Active Cdc42 was specifically
pulled down from cell lysates containing equal amounts of protein
with immobilized recombinant PAK-CRIB and analyzed by western
blotting using anti-Cdc42 antibody. A representative experiment is
shown. (b) The level of active Cdc42 was quantified by densito-
metric analysis of western blots and the amount of active Cdc42 was
normalized to the amount of total Cdc42. Cdc42 activation was







































Figure 6. Palladin is required by CAFs to promote invasion of
pancreatic cancer cells through Matrigel. (a) Fluorescently labeled
AsPC-1 tumor cells were plated together with control CAFs (AsPC-
1þCTRL) or palladin knockdown CAFs (AsPC-1þ shRNA1) or
rescued CAFs (transiently transfected with knockdown resistant
mouse palladin). AsPC-1 cells invaded across the Matrigel-coated
filter toward fetal bovine serum (FBS) containing medium in the
lower chamber. Invading AsPC-1 cells were quantified as indicated
in the Materials and methods section (NS¼not significant,
*Po0.05). (b) Western blot analysis was used to detect palladin
levels in cells treated with control shRNA (CTRL), palladin-specific







































Figure 7. Palladin is required by CAFs to promote invasion of
pancreatic cancer cells through collagen. Fluorescently labeled
AsPC-1 tumor cells were plated together with control CAFs
(AsPC-1þCTRL) or palladin knockdown CAFs (AsPC-1þ shRNA1
and AsPC-1þ shRNA2). AsPC-1 cells invaded across the collagen-
coated filter toward fetal bovine serum (FBS) containing medium in
the lower chamber. Invading AsPC-1 cells were quantified as
indicated in the Materials and methods section (NS¼not significant,
*Po0.05).
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upregulation of a GEF could result in increased activation of
GTPases and thus promote deregulation of Rho family signaling
cascades in cancer.48 Two GEFs have been implicated directly in
invadopodia/podosome formation with a role in cancer. The GEF
Arhgef5 has been shown to have crucial roles in Src-induced
podosome formation.49 Faciogenital dysplasia protein Fgd1
regulates invadopodia biogenesis and ECM degradation and is
upregulated in prostate and breast cancer.50 Our results showed
that Cdc42 activity is significantly reduced in palladin KD cells. This
could result from reduced activity of one or more GEFs or
increased activity of one or more GAPs. To date, little is known
about the role of GEFs and GAPs in invadopodia biogenesis and
function. Our future studies will focus on the identification of the
regulatory proteins that are responsible for the activation of Cdc42
downstream of palladin.
Our current results provide mechanistic insights that expand on
previously published studies that were largely correlative in
nature. Along with others, we have shown that palladin is highly
expressed in an isoform-specific pattern in the stroma of pancreas
tumors, and that this upregulation is specific to invasive
pancreatic ductal adenocarcinoma and not detected in less
invasive tumor types.12,13,37 In addition, elevated expression of
stromal palladin has been shown to predict poor clinical outcome
in renal cell carcinoma.14 A recent study has shown that
exogenous overexpression of palladin in normal fibroblasts
imparts myofibroblast properties to these cells, promoting the
invasive potential of cancer cells.37 In the current work, we used
knockdown approaches to determine the role of stromal palladin
in cancer cell invasion and extended these studies into a mouse
model. The results of both the transwell co-culture experiments
and the mouse xenograft study suggest that palladin expression
has an essential role in the pro-invasive behavior of CAFs.
Previously published co-culture experiments have shown that
CAFs possess the ability to generate channels within the ECM that
promote the migration of skin carcinoma cells, and that CAFs
enhance the metastatic behavior of cancer cells in xenograft
models.11 Our data suggest that in addition to Rho-dependent
mechanisms that create tunnels through the matrix, CAFs also use
invadopodia to degrade the matrix, and thus our results suggest
that CAFs promote the invasion of cancer cells through multiple
modes of matrix remodeling.
In conclusion, we provide novel insights into the role of palladin
and Cdc42 in CAF-mediated invasion of pancreas cancer cells.
These results suggest that the palladin/Cdc42 pathway will likely
provide new targets for molecular therapies aimed at controlling
the aggressive metastasis of pancreas cancer, one of the most
dismal pathobiological behaviors of this tumor.
MATERIALS AND METHODS
Ethics statement
All animals were handled in strict accordance with good animal practice as
defined by the relevant national and/or local animal welfare bodies, and all
animal work was approved by the Institutional Animal Care and Use
Committee.
Cell lines
Immortalized human PSCs were characterized previously.10 imPSC-C2 and
clone 3 (imPSC-C3) were characterized previously.30 Immortalized CAF,
imPSC-C2, imPSC-C3 and primary CAFs were cultured in Dulbecco’s
modified Eagle’s medium (GIBCO, Grand Island, NY, USA) supplemented
with 10% fetal bovine serum and antibiotics. Pancreatic cancer cell line
AsPC-1 was obtained from ATCC (ATCC # CRL-1682, Manassas, VA, USA).
AsPC-1 cells were cultured in RPMI supplemented with 10% fetal bovine
serum and antibiotics. All cell lines were grown at 37 1C and 10% carbon
dioxide.
Materials
The following antibodies were used: palladin polyclonal (ProteinTech
Group, Chicago, IL, USA); palladin monoclonal 1E6 previously characterized
by Parast and Otey15; tubulin alpha (Lab Vision Corporation, Fremont, CA,
USA); glyceraldehyde 3-phosphate dehydrogenase and cortactin (Santa
Cruz, Dallas, TX, USA); vinculin (Sigma, St Louis, MO, USA); Cdc42
monoclonal (BD Biosciences, Franklin Lakes, NJ, USA). Protease inhibitor

































































Figure 8. Palladin expression in CAFs enhances in vivo invasion of pancreatic cancer cells. Luciferase-expressing AsPC-1 cells were mixed with
no CAFs, control CAFs, or palladin knockdown CAFs, and injected into the pancreas. Serial bioluminescence imaging of tumors reflects
differential rates and efficiencies of tumor progression for the different mixed-cell types. (a) Representative bioluminescence images at the
indicated times (weeks) post-injection with luciferase-expressing AsPC-1 cells, mixed with either control CAFs, palladin knockdown CAFs or no
CAFs (AsPC1 alone). Each set of images was taken from the same mouse. (b) Tumor growth rates (n¼ 10 mice per group) injected with the
specified mixed-cell type, as reflected by total photon flux (photons per second) per animal over the indicated time periods. Mice were
injected with AsPC-1 cells with control CAFs (blue line), or palladin knockdown CAFs (green line), or no CAFs (red line). *Po0.05.
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TransIT-LT1 transfection reagent were from Mirus (Mirus, Madison, WI,
USA). Alexafluor-488 and Alexafluor-568 anti-mouse immunoglobulin G
and anti-rabbit immunoglobulin G-conjugated secondary antibodies were
from Molecular Probes (Molecular Probes, Eugene, OR, USA). Horseradish
peroxidase-conjugated secondary andibodies were from Jackson
Immunoresearch (Jackson Immunoresearch, West Grove, PA, USA).
Immunofluorescence staining
Cells were grown on glass coverslips and fixed in 4% paraformaldehyde in
phosphate-buffered saline (PBS), then permeabilized in 0.2% Triton X-100
and incubated with the specific primary antibodies for 1 h. Primary
antibodies were detected with Alexafluor-488 and Alexafluor-568 anti-
mouse immunoglobulin G and anti-rabbit immunoglobulin G conjugates.
Coverslips were examined with a Nikon TE200-U microscope (Nikon,
Melville, NY, USA) with 20 and 60 objective lenses, an optional 1.5
tube lens and a Hamamatsu Orca-ER camera. Images were processed using
Adobe Photoshop 7.0 (Adobe Systems Inc., New York, NY, USA).
Invadopodia formation was induced by the addition of 1 mM PDBu
(Sigma-Aldrich, St Louis, MO, USA), as previously described23,51 and PMA
as previously described.52
siRNA knockdown
The following siRNA were used in this study (sense strand): palladin,
50-CUACUCCGCUGUCACAUUAUU-30 ; Cdc42, 50-GAUAACUCACCACUGUCC
ATT-30 . As a control we used siCONTROL non-targeting siRNA #2 from
Dharmacon (Dharmacon, Lafayette, CO, USA). Cells were transfected using
the TransIT siQuest transfection reagent following the manufacturer’s
instructions. Briefly, 1.5ml of serum-free medium (Life Technologies,
Dharmacon) and 20 ml of transfection reagent per plate were preincubated
for 15min at room temperature. After incubation, 225ml of 1 mM siRNA was
added to the diluted TransIT siQuest reagent and the mixture was
incubated for 15min at room temperature for complex formation. Then,
the entire mixture was added to the cells, resulting in a final concentration
of 25 nM siRNAs. Cells were assayed between 72 and 96 h after transfection.
Cell lysis and immunoblot
Cells cultured on 100mm tissue culture dishes were briefly rinsed with PBS
and then scraped into a lysis buffer containing 50mM Tris (pH 7.0), 150mM
NaCl, 1% Triton X-100, and a protease inhibitor cocktail for mammalian
tissues. The supernatant was collected after centrifugation at 14 000 r.p.m.
for 15min. The cell lysates were either analyzed by immunoblot or
processed for migration and invasion assays or frozen with liquid nitrogen
and stored at  80 1C for future use. For the immunoblot, lysates were
boiled in 2X Laemmli buffer, and 20mg of protein were resolved by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis in each lane of a
4–12% gel. The proteins were transferred to nitrocellulose and immuno-
blotted. Immunocomplexes were visualized using the Western Lights
Chemiluminescence Detection kit from Perkin-Elmer (Perkin Elmer,
Waltham, MA, USA).
In vitro ECM degradation assay
Cells were seeded onto coverslips that were coated with fluorescein
isothiocyanate-conjugated gelatin for an in vitro ECM degradation assay, as
described previously.28 Briefly, glass coverslips were coated overnight with
100 lg/ml fluorescein isothiocyanate-labeled gelatin in PBS and fixed with
0.5% glutaraldehyde, washed six times with PBS, incubated with 50 lg/ml
fibronectin at room temperature for 1 h, then washed once with 70%
ethanol/PBS and once with medium. Cells were plated onto the coverslips
and incubated at 37 1C in an incubator with 5% CO2 for up to 24 h. Cells
were fixed, permeabilized and incubated with 1% bovine serum albumin
to block nonspecific staining and the F-actin was stained with rhodamine-
conjugated phalloidin. The coverslips were examined using a Nikon Eclipse
TE2000-U fluorescent microscope. The images were captured and
analyzed, and the percentage of total area that was degraded was
calculated using Nikon NIS Elements imaging software (Nikon).
Co-culture invasion assay
The invasiveness of pancreatic cancer cells was assessed based on the
number of cells invading through either Matrigel-coated transwell
chambers (BD Biosciences) or collagen-coated transwell chambers
(Millipore, Billerica, MA, USA). AsPC-1 cells were fluorescently labeled with
CellTracker red for quantification, then placed in the upper chamber
together with control CAFs (AsPC-1þCTRL) or with CAFs in which palladin
was stably knocked down using shRNA delivered by lentivirus. The stable
knockdown line is designated shRNA1. To restore palladin expression in
the stable knockdown cells, knockdown resistant full-length mouse
palladin was transiently expressed using an adenoviral vector, as
previously described.17 AsPC-1 with no CAFs were used as a control
(AsPC-1 alone). The cells were allowed to invade for 24 h; then the non-
invading cells were removed from the upper well. The invading cells were
fixed and the red AsPC-1 cells were counted. The assay was performed at
least two times in triplicate for each group.
Lentiviral constructs and transduction
GIPZ lentiviral shRNAmir (control non-silencing and human palladin
shRNA) vectors (clone ID. V3LHS_310865; shRNA1 and V3LHS_310862;
shRNA2 and gene access no. NM_016081) were obtained from Open
Biosystem, Huntsville, AL, USA. Lentiviral packaging was done in TLA-
HEK293T cells in accordance with the Trans-Lentiviral packaging system
(Open Biosystems). After 12 h of transfection, the packaging cocktail was
aspirated and replaced with complete medium. After 72 h, lentiviral
containing supernatants were collected, centrifuged at 3000 r.p.m. for
20min and stored at  80 1C for further use. PSC cells were transduced
with lentiviral stock (shRNA1 and shRNA2) overnight. The following day,
the infection media was removed and replaced with complete medium
containing puromycin (2mg/ml) to select for shRNA1, shRNA2 or control
(CTRL) shRNA-expressing cells and total cell lysates were subjected to
western blot analysis for palladin expression as described.
Cdc42 activity assay
For the Cdc42 activation assay, cells were lysed in 600ml of 50mM Tris, pH
7. 4, 10mM MgCl2, 150mM NaCl, 1% Triton X-100, and protease inhibitors.
Lysates were cleared at 16 000 g for 5min. Supernatants were rotated with
50mg GST-PBD (GST fusion protein containing the Rac/Cdc42 binding
domain of PAK1) prebound to glutathione-Sepharose beads (GE, Fairfield,
CT, USA). Beads were washed, resuspended in sodium dodecyl sulfate
sample buffer and bound material was separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis, transferred to nitrocellulose
and immunoblotted for Cdc42.
Orthotopic model of pancreatic cancer
All animal experiments were reviewed by the University of North Carolina
at Chapel Hill Institutional Animal Care and Use Committee. An orthotopic
NSG mouse model of pancreatic cancer utilizing AsPC-1 pancreatic tumor
cells labeled with firefly luciferase was used. Mice were divided into groups
receiving intrapancreatic injections of (a) AsPC-1 cells alone, 0.5 106 per
mouse; (b) AsPC-1 with control CAFs (tumor cell to CAF ratio 1:3); or (c)
AsPC-1 with palladin stable knockdown CAFs (shRNA1), in a ratio of 1:3
(tumor cell to CAF). All cell suspensions, including the mixtures of AsPC-1
and CAFs, were injected in a 21ml volume of Dulbecco’s modified Eagle’s
medium. Bioluminescent imaging was performed weekly to quantify and
localize the luciferase signal from AsPC-1 cells.
Statistical analysis
Data were analyzed using a two-tailed unpaired Student’s t-test. A P-value
of o0.05 was considered significant.
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